Gelesis

IPO

Hydrogel-Based Medical Devices for Weight Management

Public · Boston, United States · Founded 2008 · $185.5M raised

Founded
2008
Business Model
B2B
Total Funding
$185.5M
Last Round
$84.0M Series DJan 2021
Rounds
5
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Obesity is a chronic, multifactorial disease influenced by biology. Gelesis develops GI and metabolic based biomimetic therapies designed to support physiology and long-term health outcomes. By working locally in the GI tract, its oral materials-based superabsorbent hydrogel aims to influence satiety-related signals and support metabolic health, grounded in measurable mechanisms and clinical validation.

Summary

Gelesis is a Biotech company based in Boston, United States, founded in 2008. It has raised $185.5M in total across 5 rounds, most recently a $84.0M Series D round in Jan 2021. Investors include Capstar Special Purpose Acquisition Corp, PureTech Health and OrbiMed.

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

SPAC MergerSPAC MergerJan 2022

Sign up to see all 6 events

Funding: Series A through Series D. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Gelesis on Indexed.vc
<a href="https://indexed.vc/companies/gelesis"><img src="https://indexed.vc/api/badge/company/gelesis" alt="Gelesis on Indexed.vc" width="260" height="76" /></a>